MedTrace Logo

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

NCT05096715 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-02-18

No results posted yet for this study

Summary

This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable hepatocellular carcinoma.

This study involves the following interventions:

* Atezolizumab
* Bevacizumab
* Stereotactic body radiation therapy (SBRT)

Conditions

Interventions

DRUG

Atezolizumab

Intravenous Infusion

DRUG

Bevacizumab

Intravenous Infusion

RADIATION

Stereotactic body radiation therapy (SBRT)

External Beam Radiation

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Jennifer Y Wo, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-23
Primary Completion
2027-01-31
Completion
2032-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05096715 on ClinicalTrials.gov